KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 109 filers reported holding KALA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 3.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $26,000 | -50.0% | 9,750 | 0.0% | 0.01% | -41.7% |
| Q2 2021 | $52,000 | +44.4% | 9,750 | +80.7% | 0.01% | +50.0% |
| Q1 2021 | $36,000 | -43.8% | 5,397 | -42.7% | 0.01% | -50.0% |
| Q4 2020 | $64,000 | +33.3% | 9,415 | +46.8% | 0.02% | +23.1% |
| Q3 2020 | $48,000 | +6.7% | 6,415 | +50.7% | 0.01% | 0.0% |
| Q2 2020 | $45,000 | -54.5% | 4,256 | -62.2% | 0.01% | -64.9% |
| Q1 2020 | $99,000 | +350.0% | 11,250 | +150.0% | 0.04% | +236.4% |
| Q4 2018 | $22,000 | – | 4,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |